Eplerenone, Aflibercept and Topical Nepafenac Serous Foveal Deta Chment in Central Serous Chorioretinopathy
NCT ID: NCT05847049
Last Updated: 2023-05-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
16 participants
OBSERVATIONAL
2023-02-28
2023-04-06
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601-004)
NCT00616993
A Study of the Effect of Different Doses of Difluprednate Eye Drops on the Intraocular Pressure After Phacoemulsification
NCT05649111
Role of Nepafenac in Reducing Macular Volume After Epiretinal Membrane Surgery
NCT00818844
Treatment of CNV With Aflibercept Combined With Pranoprofen Eye Drops or Nutraceutical Support With Omega-3
NCT03355638
Treatment of Macular Edema After Cataract Surgery with Subconjunctival Aflibercept
NCT03396861
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
After checking inclusion and exclusion criteria; we will enroll all cases that have been treated by the combination of eplerenone, intravitreal aflibercept and topical nepafenac.
Investigators collected and recorded the following data:
* Age
* Gender
* Systemic hypertension (present or not)
* Smoking (Yes / No)
* Best corrected visual acuity (BCVA) (baseline, final)
* Central macular thickness (CMT) (baseline, final)
* Serous detachment Height (SDH) (baseline, final)
* Duration of Follow-up ( in months)
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Eplerenone , Intravitreal Aflibercept and Topical nepafenac therapy
Eplerenone , Intravitreal Aflibercept and Topical nepafenac therapy
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* CSCR treated by just 1 or 2 components of :Eplerenone, Aflibercept and Nepafenac
16 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Dar El Oyoun Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Wael Ahmed Ewais
Associate professor of ophthalmology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kasr alainy faculty of medicine
Cairo, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
N-20-2023
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.